Avail Clinical Research Announces Gastroesophageal Reflux Disease Research Studies in DeLand, FL

DeLand, FL, February 26, 2010 --(PR.com)-- Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, FL, announces the launch of several research studies to test investigational treatment options for those already diagnosed with gastroesophageal reflux disease (GERD). “We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from gastroesophageal reflux disease,” said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. “We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for GERD." Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with gastroesophageal reflux disease, which includes symptoms like persistent heartburn, sour or bitter taste in the mouth, and chest pain. In order to participate in the studies volunteers must be diagnosed with gastroesophageal reflux disease. Avail Clinical Research will not take volunteers who:

· have any evidence or treatment of malignancy within the previous 5 years,
· have a history of alcohol or substance abuse within the previous 5 years,
· have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
· are pregnant, or
· are breast-feeding.

Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our research studies, contact Avail Clinical Research at 386.310.1334, or at www.AvailClinical.com.

###